"The reduction in revenue due to Zyprexa patent expirations is expected to be partially offset by growth in key franchises including Cymbalta, Cialis®, Humalog®, Humulin® and Forteo®, as well as continued growth of newer products such as Effient®, Axiron® and Tradjenta®."
this implies that Axiron will be a material contributor to group revenue growth.
pretty awesome to be mentioned in the same sentence as blockbuster names like cymbalta and cialis!
ACR Price at posting:
$2.97 Sentiment: Buy Disclosure: Held
